.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 6,878,703

« Back to Dashboard

Claims for Patent: 6,878,703

Title: Pharmaceutical composition
Abstract:A pharmaceutical composition comprises an angiotensin II receptor antagonist selected from among compounds having the following formula (I), a pharmacologically acceptable salt thereof, a pharmacologically acceptable ester thereof and a pharmacologically acceptable salt of such ester, and one or more diuretics: ##STR1## The pharmaceutical composition of the present invention has an excellent hypotensive effect and low toxicity, and therefore is useful as a medicament for preventing or treating hypertension or heart disease.
Inventor(s): Sada; Toshio (Tokyo, JP), Mizuno; Makoto (Funabashi, JP)
Assignee: Sankyo Company, Limited (Tokyo, JP)
Application Number:10/442,874
Patent Claims: 1. A method for treating hypertension comprising administering to a warm-blooded animal in need thereof a pharmaceutically effective amount of each of (i) an angiotensin II receptor antagonist selected from the group consisting of a compound having the following formula (I): ##STR10##

a pharmacologically acceptable salt thereof, a pharmacologically acceptable ester thereof and a pharmacologically acceptable salt of said ester thereof, and (ii) a diuretic which is hydrochlorothiazide.

2. The method according to claim 1, wherein the warm-blooded animal is a human.

3. The method according to claim 2, wherein the angiotensin II receptor antagonist is the compound of the formula (I) or a pharmacologically acceptable ester hereof.

4. The method according to claim 2, wherein the angiotensin II receptor antagonist is a pharmacologically acceptable ester of the compound of the formula (I).

5. The method according to claim 2, wherein the angiotensin II receptor antagonist is the pivaloyloxymethyl ester, phthalidyl ester, or (5-methyl-2-oxo-1,3-dioxolen-4-yl)methyl ester of the compound of the formula (I).

6. The method according to claim 2, wherein the angiotensin II receptor antagonist is the (5-methyl-2-oxo-1,3-dioxolen-4-yl)methyl ester of the compound of th formula (I).

7. The method according to claim 2, wherein the diuretic further comprises one or more diuretics selected from the group consisting of methylclothiazide, benzyl-hydrochlorothiazide, trichlormethiazide, cyclopenthiazide, polythiazide, ethiazide, cyclothiazide, bendroflumethiazide and hydroflumethiazide.

8. The method according to claim 2, wherein a weight ratio of amounts of the compound of the formula (I) to the diuretic is 1:200 to 200:1.

9. The method according to claim 3, wherein a weight ratio of amounts of the compound of the formula (I) to the diuretic is 1:200 to 200:1.

10. The method according to claim 5, wherein a weight ratio of amounts of the compound of the formula (I) to the diuretic is 1:200 to 200:1.

11. The method according to claim 2, wherein the compound of the formula (I) is administered at least once a day in an amount of 0.5 to 1,000 mg and the diuretic is administered at least once a day in an amount of 0.05 to 1,500 mg.

12. The method according to claim 2, wherein the compound of the formula (I) is administered at least once a day in an amount of 1 to 100 mg and the diuretic is administered at least once a day in an amount of 5 to 300 mg.

13. The method according to claim 6, wherein a weight ratio of amounts of the compound of the formula (I) to the diuretic is 1:200 to 200:1.

14. The method according to claim 6, wherein the compound of the formula (I) is administered at least once a day in an amount of 0.5 to 1,000 mg and the diuretic is administered at least once a day in an amount of 0.05 to 1,500 mg.

15. The method according to claim 6, wherein the compound of the formula (I) is administered at least once a day in an amount of 1 to 100 mg and the diuretic is administered at least once a day in an amount of 5 to 300 mg.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc